Is CBD legal in Slovenia?

25 August 2026

A flag of Slovenia, next to the chemical structure of CBD

Situación formal

Under Regulation (EU) 2015/2283, CBD has been treated as a novel food across the entire EU since January 2019 — and no member state has yet authorised it. EFSA's February 2026 provisional safe intake figure (roughly 2mg/day for a 70kg adult) is a safety opinion, not an authorisation.

Slovenia's medicines agency takes the same view, stating that CBD intended for ingestion, including CBD extracts, is classified as an unauthorised novel food, that this covers any product to which cannabinoids are added as an ingredient, and that such products may not be placed on the market.

But the decisive Slovenian instrument is not food law. It is the drugs schedule. The Decree on the classification of illicit drugs places cannabis in Group II, in an entry covering the plant, its resin and its extracts. The entry carries no THC threshold and no quantitative carve-out of any kind. Under the governing statute, Group II substances may be produced, traded and possessed only for medical, veterinary, teaching and scientific-research purposes, and may be placed in trade only with ministerial authorisation.

The courts have read this strictly. The Supreme Court has held that trade in a substance listed in the decree is prohibited regardless of the form and quantity in which it is placed on the market, citing earlier criminal judgments that any listed cannabis is a prohibited drug regardless of its THC content. The criminal offence carries one to ten years' imprisonment.

Cannabidiol itself is not listed in the decree. What places it there is that it arrives in an extract of the listed plant.

¿Vendemos aquí?

No.

No, we do not ship to Slovenia, and the reason is more serious than in most countries we have had to decline.

Slovenia's drugs schedule lists cannabis extracts among its controlled substances, with no THC threshold and no low-strength exception — see the full detail above. Slovenian courts have read that literally, and the criminal penalty for trade in a listed substance runs one to ten years.

We should be fair about the other side of this. Slovenia's own medicines agency describes CBD as an unauthorised novel food rather than a controlled drug, its health inspectorate has taken no action on CBD in five years, and a 2020 European court ruling held that member states may not block CBD lawfully produced elsewhere in the EU. Slovenian shops do sell CBD products.

We have chosen to follow the written law rather than enforcement practice here. A criminal statute carrying a one-to-ten-year penalty is not a risk we are willing to take on our customers' behalf, however unlikely enforcement may look.

We review this regularly and would genuinely like to be wrong. If Slovenia clarifies that its rule does not reach low-THC extracts, we will say so here and open the market.

Perspectivas

There is a genuine and unresolved tension in the Slovenian position, and it is the thing most likely to move.

The drugs schedule, read literally, treats every cannabis extract as a controlled substance. But the Court of Justice held in November 2020 that a member state may not prohibit the marketing of CBD lawfully produced in another member state where it is extracted from the whole plant. Slovenia's own health inspectorate described that judgment as a turning point in its annual report and its CBD inspection campaign never resumed. Meanwhile the medicines agency frames CBD as a novel food question rather than a drugs question, and in June 2026 a Slovenian producer's 10% CBD oil was recalled over a THC contaminant rather than over the CBD or the extract's status at all.

A published position from either agency, or a single court decision on whether the extract entry reaches a low-THC CBD product, would settle the question in one step. Until then the written law is what it is.

A new medical cannabis act took effect in August 2025. It does not relax the position for food products - it excludes the plant and its parts grown for food and industrial purposes, but pointedly not extracts.

Timeline

May 2012

Slovenia's Supreme Court, Sklep X Ips 17/2012, holds that trade in a substance listed under the Decree is prohibited regardless of the form or quantity involved, except where the law specifically provides otherwise. The judgment's own footnote cites I Ips 157/2008 and I Ips 158/2008 (27 November 2008) and I Ips 138/2006 (28 June 2007) for the same proposition - any cannabis listed in the decree is a prohibited drug regardless of THC content. Note: this is a procedural order rejecting revision as inadmissible, not a full judgment on the merits, and it was decided when cannabis sat in Skupina I.

Vrhovno sodišče RS, ECLI:SI:VSRS:2012:X.IPS.17.2012

November 2019

Uredba o razvrstitvi prepovedanih drog (Ur. l. RS 69/19), adopted 21 November 2019, published 22 November 2019 and in force 7 December 2019, places cannabis in Skupina II at entry 112: "KONOPLJA — Cannabis sativa L. — ekstrakti / rastlina / smola". The entry carries no THC threshold and no quantitative carve-out. Made under ZPPPD, whose article 7(2) permits Group II trade only for medical, veterinary, teaching and scientific-research purposes and whose article 10(1) requires ministerial authorisation. Amended through Ur. l. RS 157/20, 162/21, 8/23, 113/23, 50/25 and 92/25 without change to entry 112 beyond a footnote cross-referring to ZKMZN.

Uradni list RS št. 69/2019

February 2020

The Higher Court in Maribor, Sodba II Kp 5584/2016, held in a cross-border online drug-sales case that which country a drug was delivered from and to is not decisive: the sale of a prohibited drug is already complete once buyer and seller agree on quantity and price, and the offence doesn't require that the goods ever actually reach the buyer. The court applied the territoriality principle and the ubiquity theory under KZ-1 article 19. On this reasoning, a foreign seller's exposure crystallises when the order is accepted, not when the parcel is dispatched.

Višje sodišče v Mariboru, ECLI:SI:VSMB:2020:II.KP.5584.2016

November 2020

The Court of Justice of the European Union gives judgment in C-663/18 (Kanavape), holding that a Member State may not prohibit the marketing of CBD lawfully produced in another Member State where it is extracted from the Cannabis sativa plant in its entirety. Slovenia's Health Inspectorate records the judgment in its 2020 annual report as a landmark ruling, and its 2019 CBD inspection campaign does not resume in any subsequent reporting year.

Court of Justice of the European Union, C-663/18

August 2025

The Cannabis for Medical and Scientific Purposes Act (ZKMZN, Official Gazette RS 60/25), published 5 August 2025 and in force from 20 August 2025. Article 2(6) defines cannabis for medical purposes to include extracts from cannabis regardless of THC content, as well as other naturally occurring cannabinoids. Article 3(1) excludes the plant and its parts grown from catalogue varieties for food and industrial purposes, but not extracts. Article 2(16) redefines import to expressly include inbound movement from other EU member states, abandoning ZPPPD's customs-territory anchor. It repeals and amends nothing in ZPPPD.

Uradni list RS št. 60/2025

June 2026

ZIRS orders a recall of "CBD kapljice, 1000 mg, 10%" (Agrosloven z.o.o., Golnik; distributed by Be Healthy d.o.o., Šenčur), triggered by a RASFF notification, on the ground that the THC present (292.5 mg/kg) in the food supplement may pose a risk to human health. Both producer and distributor are Slovenian-established. The objection was the THC content, not the CBD or the product's novel-food status - and a Slovenian producer had been openly selling a 10% CBD oral supplement until this point.

Zdravstveni inšpektorat RS — Nevarni in neskladni izdelki

Ingredientes

Consultar la legalidad de nuestros otros ingredientes en Slovenia.